NovAccess Global Inc. announced a partnership with CKN Ventures Limited to expand clinical data set access in Southeast Asia to enhance and accelerate therapeutics and treatment protocols. This partnership supports NovAccess Global's new Precision Medicine Division, launched earlier this month, to develop the most comprehensive collection of therapeutics and treatment protocols using artificial intelligence (AI), Big Data and Predictive technologies. Using advances in AI, image recognition and predictive data science, NovAccess Global and CKN Ventures will collaborate to expand access to relevant data sources in Asia that will improve the quality and impact of licensed databases to identify patient data (phenotypic, clinical, and genomic) for analysis relating to therapeutic drug development and therapeutic treatment purposes.

Therapeutic and treatment protocol data will be marketed to external pharmaceutical and biotechnology companies, private payers, national/international health agencies and healthcare providers and insurers. NovAccess Global intends to also use AI within these data sets to identify the most optimal antigensto use for dendritic cell vaccines. Antigens are the molecules that trigger the immune response, and they need to be specific for the tumor cells and not the normal cells.

AI can analyze the genomic and proteomic data of tumor cells and find the most suitable antigens for each patient. It is NovAccess Global's belief that AI can help to optimize the dose and timing of dendritic cell vaccines. The dose and timing of the vaccine can affect the efficacy and safety of the treatment.

AI can use mathematical models and machine learning algorithms to predict the optimal dose and timing based on various factors such as the patient's characteristics, the tumor type and stage, and the immune status.